Yearly Archives: 2009

­

Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials

November 19th, 2009|

With IND Now Open, Fifth Clinical Study, in Ocular Neuroprotection, Set to Begin in 1Q10

Fremont, CA – November 19, 2009 – Quark Pharmaceuticals, Inc., the leader in siRNA therapeutics in clinicals, announced today that four of its siRNA R&D platform based programs have met clinical development milestones; patient enrollment was completed in three clinical studies […]

Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases

November 2nd, 2009|

Fremont, CA – November 2, 2009 – Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the […]

Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene

October 26th, 2009|

FREMONT, Calif. Oct. 26 — Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, “Hypoxia regulated genes,” on August 7, 2009. Granted to Quark from a Japanese National Phase application of International (PCT) Patent Application No. PCT/US98/17296, the patent corresponds […]

Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference

August 3rd, 2009|

Fremont, CA – August 3, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC’s Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in […]

Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma

July 27th, 2009|

Fremont, CA – July 27, 2009, — Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in an increased ocular pressure (IOP) rat model of glaucoma. The experiments performed by Prof. Adriana Di Polo of the Department […]

Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

June 9th, 2009|

Fremont, CA – June 9, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Bruce A. Molitoris, M.D., Director, Division of Nephrology and Professor of Medicine, Indiana University, will present data demonstrating efficacy in models of acute and chronic kidney disease (AKI and CKD, respectively) of […]

Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage

May 14th, 2009|

Fremont, CA – May 14, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “siRNA Therapeutics for Prevention of Ocular and Inner Ear Sensory Cells Death,” at the DxRx Summit: Nucleic Acid Diagnostics […]

Pfizer and Quark

May 11th, 2009|

Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

May 11th, 2009|

Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]

Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

April 20th, 2009|

Fremont, CA – April 20, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 21 at this year’s American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which […]